

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Additionally, BioCryst has a third product candidate, BCX4208—a next generation PNP inhibitor—in mid-stage trials for the treatment of gout. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's Web site at www.biocryst.com.

Key Financials

| | |
|---|----------|
| NASDAQ: | BCRX |
| Common Shares Outstanding (06/30/10): | 44.9 M |
| Cash, Cash Equivalents & Securities (06/30/10): | \$81.2 M |



BioCryst Pharmaceuticals

Birmingham, AL Office

2190 Parkway Lake Drive
Birmingham, Alabama 35244
Phone (205) 444-4600
Fax (205) 444-4640

Durham, NC Office

4505 Emperor Blvd, Suite 200
Durham, NC 27703
Phone (919) 859-1302
Fax (919) 851-1416

www.biocryst.com

Email: info@biocryst.com

INFECTIOUS DISEASES

PRE-CLINICAL PHASE 1 PHASE 2 PIVOTAL FILED APPROVED

Peramivir Outpatient Flu
(SEASONAL INFLUENZA / I.V.)



SHIONOGI & CO., LTD.

Peramivir Hospitalized Flu
(ACUTE INFLUENZA / I.V.)



CANCER

PRE-CLINICAL PHASE 1 PHASE 2 PIVOTAL FILED APPROVED

Forodesine
(CTCL)



Forodesine
(CLL)



Forodesine
(ALL)



INFLAMMATORY DISEASES

PRE-CLINICAL PHASE 1 PHASE 2 PIVOTAL FILED APPROVED

BCX4208
(GOUT)



Management Team

Jon P. Stonehouse

President, Chief Executive Officer

Stuart R. Grant, B Acc, CA

SVP, Chief Financial Officer

William P. Sheridan, MB BS

SVP, Chief Medical Officer

Yarlagadda S. Babu, PhD

VP, Drug Discovery

Alane Barnes, JD

General Counsel & Corporate Secretary

Elliott T. Berger, PhD

SVP, Regulatory Affairs

Walter G. Gowan, PhD

VP, Pharmaceutical Development

David S. McCullough

VP, Strategic Planning,
Commercialization & Corporate Development

Peter L. McCullough

VP, Operations

Robert C. Stoner, SPHR

VP, Human Resources

Board of Directors

Zola P. Horovitz, PhD

Chairman

Stephen R. Biggar, MD, PhD

Stanley C. Erck

William W. Featheringill

John L. Higgins

Charles A. Sanders, MD

Beth C. Seidenberg, MD

Jon P. Stonehouse

Contact Information

Robert Bennett, BioCryst, Executive Dir.

Business Development & Investor Relations
(919) 859-7910

Investorrelations@biocryst.com

Catherine Collier Kyroulis, WCG

Media Relations
(212) 301-7174

ckyroulis@wcgworld.com



August 2010

Peramivir

Peramivir is a potent, intravenously administered anti-viral agent that rapidly delivers high plasma concentrations to the sites of infection. Discovered by BioCryst, peramivir inhibits the interactions of influenza neuraminidase, an enzyme that is critical to the spread of influenza within the host.

- Intravenous (i.v.) peramivir is currently approved in South Korea and Japan to treat patients with influenza. BioCryst's partner, Green Cross Corporation received marketing and manufacturing authorization for i.v. peramivir in South Korea in August 2010 and Shionogi & Co., Ltd. launched i.v. peramivir in Japan under the name Rapiacta® in January 2010.
- BioCryst is conducting two Phase 3 studies of i.v. peramivir for the treatment of seriously ill patients hospitalized with influenza. These studies are intended to support U.S. regulatory approval.
- According to the Centers for Disease Control & Prevention (CDC), more than 200,000 patients are hospitalized and 36,000 people die from flu-related complications each year in the U.S.
- There is a significant need for an injectable treatment option for patients hospitalized with influenza. No parenteral anti-viral treatment for influenza is currently approved for use in hospitalized patients.

Forodesine

Forodesine is an orally-available transition-state analog inhibitor of purine nucleoside phosphorylase (PNP), a purine salvage pathway enzyme that is essential for the proliferation of T-cells and B-cells.

- Forodesine is highly target specific, inducing apoptosis in both T-cells and B-cells.
- BioCryst is currently conducting a pivotal study for cutaneous T-cell lymphoma (CTCL) under a special protocol assessment (SPA) with the FDA. Data is expected in the second half of 2010.
- CTCL affects about 18,000 people in the U.S. Unlike most cancer patients, CTCL patients are treated chronically, and some could benefit from an oral agent that is generally safe and well-tolerated like forodesine.
- Forodesine is also being studied in an exploratory Phase 2 study in chronic lymphocytic leukemia (CLL). Data is expected in the second half of 2010.
- Approximately 15,000 people are diagnosed with CLL in the U.S. each year. Current treatment is inadequate, with improvement needed in both outcomes and tolerability.
- Forodesine's novel mechanism of action, oral administration, and excellent safety and tolerability make it an attractive therapeutic candidate for both CTCL and CLL alone or in combination with other chemotherapeutics.

BCX4208

BCX4208 is a next generation PNP inhibitor with the potential for once-a-day dosing for chronic administration.

- BioCryst reported positive top-line data, demonstrated dose response and completed its Phase 2 monotherapy study of BCX4208 in patients with gout in July 2010.
- In June 2010, BioCryst initiated enrollment in an additional Phase 2 study to evaluate the efficacy and safety of BCX4208 alone and in combination with allopurinol in patients with gout; results are expected by the end of 2010.
- Gout affects approximately more than 5.1 million individuals in the U.S. and is the most common inflammatory arthritis in males. Lifestyle and diet trends in the U.S. and globally, will lead to significant increases in the number of gout sufferers by 2020. Presently, there is no cure for gout and current treatments provide only temporary symptomatic relief.
- With its unique mechanism of action, clinical activity and safety in clinical studies to date, and potential synergy with approved therapies, BCX4208 has the potential to address unmet medical needs across a broad spectrum of inflammatory and autoimmune diseases.

Forward-looking Statements

This fact sheet contains historical information, as well as forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this document. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.